NEW YORK, New York — When data were combined from two parallel phase 3 bronchiectasis treatment trials, inhaled colistimethate sodium failed to significantly reduce the rate of exacerbations associated with Pseudomonas aeruginosa infection, but the disparity in the findings from the two trials, presented at the 6th World Bronchiectasis &…Read More
Related Posts
DiaMedica Therapeutics Announces 375 Million Private Placement
MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases (âDiaMedicaâ or the âCompanyâ), today announced it has…
What happens when a 2 million gene therapy is not enough By Reuters
LOS ANGELES (Reuters) - Baby Ben Kutschke was diagnosed at three months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy…
Shed Rx is Launching its SHED500 SHED1000 and SHED1500 Semaglutide Lozenges in Select States throughout…
Phoenix, AZ - The development of safe weight loss treatment is never-ending, thanks to technological advancements and research in the medical field. Semaglutide, the newest medication, is an injectable drug…
